世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

神経内分泌腫瘍治療の世界市場インサイト、2030年までの予測


Global Neuroendocrine Tumor Treatment Market Insights, Forecast to 2030

神経内分泌腫瘍(NETs)は、内分泌(ホルモン)系および神経系の細胞から発生する新生物である。多くは良性であるが、一部は悪性である。NETは腸に発生することが最も多く、カルチノイド腫瘍と呼ばれることもある... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年8月15日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

神経内分泌腫瘍(NETs)は、内分泌(ホルモン)系および神経系の細胞から発生する新生物である。多くは良性であるが、一部は悪性である。NETは腸に発生することが最も多く、カルチノイド腫瘍と呼ばれることもあるが、膵臓、肺、その他の部位にもみられる。

市場分析と洞察神経内分泌腫瘍治療の世界市場
世界の神経内分泌腫瘍治療市場は、2024年の1億6,320万米ドルから2030年には2億3,030万米ドルに成長すると予測され、予測期間中の年間平均成長率(CAGR)は5.9%である。
世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

レポートの対象
本レポートでは、神経内分泌腫瘍治療の世界市場規模について概観します。2019年~2023年の過去の市場収益データ、2024年の推定値、2030年までのCAGR予測による世界市場動向の分析。
神経内分泌腫瘍治療の主要生産者を調査し、主要地域・国の収益も掲載しています。神経内分泌腫瘍治療の今後の市場ポテンシャルと、この市場を様々なセグメントとサブセグメントに予測するための主要地域/国の注目点のハイライト。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データと市場価値分析。

本レポートは、2019年から2024年までのデータで、神経内分泌腫瘍治療の収益、市場シェア、主要企業の業界ランキングに焦点を当てています。世界の神経内分泌腫瘍治療市場における主要な利害関係者を特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づいて分析します。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。
本レポートでは、2019年から2030年までのタイプ別、用途別のセグメントデータ、収益、成長率を分析しています。神経内分泌腫瘍治療の収益、予測成長動向、生産技術、用途、エンドユーザー産業の市場規模を評価・予測します。

市場区分
企業別
エクセリクシス社
アドバンスト・アクセラレーター・アプリケーション
ドーントレス社
ハッチンソン・メディファーマ・リミテッド
イスペン
ノバルティスAG
プロジェニクス・ファーマシューティカルズ社
タルベダ・セラピューティクス
タイプ別セグメント
エベロリムス
スニチニブ
Lu-ドタテート
ランレオチド
オクトレオチド
用途別セグメント
病院
クリニック
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
北欧諸国
その他の欧州諸国
中国
アジア(中国を除く)
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ、中東、アフリカ
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

各章の概要
第1章:報告書のスコープ、各市場セグメント(製品タイプ、用途など)の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介。市場の現状と、短期・中期・長期的な展開の可能性について、ハイレベルな見解を提供しています。
第2章 神経内分泌腫瘍治療の世界・地域レベルでの収益各地域とその主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、生産能力などを紹介しています。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析などを紹介します。
第3章:神経内分泌腫瘍治療薬企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報などを詳細に分析。
第4章:タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、発展の可能性をカバーし、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのに役立ちます。
第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、発展の可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第6章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の収益。
第7章:ヨーロッパ:タイプ別、用途別、国別、セグメント別収益。
第8章:中国:タイプ別、用途別、セグメント別収益。
第9章:アジア(中国を除く):タイプ別、用途別、地域別、各セグメントの収益。
第10章:中東、アフリカ、ラテンアメリカ:タイプ別、用途別、国別、セグメント別収益。
第11章:主要企業のプロフィールを提供し、製品の説明や仕様、神経内分泌腫瘍治療の収益、売上総利益率、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介する。
第12章:アナリストの視点/結論


ページTOPに戻る


目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Everolimus
1.2.3 Sunitinib
1.2.4 Lu-Dotatate
1.2.5 Lanreotide
1.2.6 Octreotide
1.3 Market by Application
1.3.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Tumor Treatment Market Perspective (2019-2030)
2.2 Global Neuroendocrine Tumor Treatment Growth Trends by Region
2.2.1 Neuroendocrine Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuroendocrine Tumor Treatment Historic Market Size by Region (2019-2024)
2.2.3 Neuroendocrine Tumor Treatment Forecasted Market Size by Region (2025-2030)
2.3 Neuroendocrine Tumor Treatment Market Dynamics
2.3.1 Neuroendocrine Tumor Treatment Industry Trends
2.3.2 Neuroendocrine Tumor Treatment Market Drivers
2.3.3 Neuroendocrine Tumor Treatment Market Challenges
2.3.4 Neuroendocrine Tumor Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Neuroendocrine Tumor Treatment by Players
3.1.1 Global Neuroendocrine Tumor Treatment Revenue by Players (2019-2024)
3.1.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neuroendocrine Tumor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neuroendocrine Tumor Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Neuroendocrine Tumor Treatment Market Concentration Ratio
3.4.1 Global Neuroendocrine Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Treatment Revenue in 2023
3.5 Global Key Players of Neuroendocrine Tumor Treatment Head office and Area Served
3.6 Global Key Players of Neuroendocrine Tumor Treatment, Product and Application
3.7 Global Key Players of Neuroendocrine Tumor Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Tumor Treatment Breakdown Data by Type
4.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Type (2019-2024)
4.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Type (2025-2030)
5 Neuroendocrine Tumor Treatment Breakdown Data by Application
5.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Application (2019-2024)
5.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuroendocrine Tumor Treatment Market Size (2019-2030)
6.2 North America Neuroendocrine Tumor Treatment Market Size by Type
6.2.1 North America Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
6.2.2 North America Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
6.2.3 North America Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
6.3 North America Neuroendocrine Tumor Treatment Market Size by Application
6.3.1 North America Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
6.3.2 North America Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
6.3.3 North America Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
6.4 North America Neuroendocrine Tumor Treatment Market Size by Country
6.4.1 North America Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
6.4.3 North America Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neuroendocrine Tumor Treatment Market Size (2019-2030)
7.2 Europe Neuroendocrine Tumor Treatment Market Size by Type
7.2.1 Europe Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
7.2.2 Europe Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
7.2.3 Europe Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
7.3 Europe Neuroendocrine Tumor Treatment Market Size by Application
7.3.1 Europe Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
7.3.2 Europe Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
7.3.3 Europe Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
7.4 Europe Neuroendocrine Tumor Treatment Market Size by Country
7.4.1 Europe Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
7.4.3 Europe Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Neuroendocrine Tumor Treatment Market Size (2019-2030)
8.2 China Neuroendocrine Tumor Treatment Market Size by Type
8.2.1 China Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
8.2.2 China Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
8.2.3 China Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
8.3 China Neuroendocrine Tumor Treatment Market Size by Application
8.3.1 China Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
8.3.2 China Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
8.3.3 China Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Neuroendocrine Tumor Treatment Market Size (2019-2030)
9.2 Asia Neuroendocrine Tumor Treatment Market Size by Type
9.2.1 Asia Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
9.2.2 Asia Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
9.2.3 Asia Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
9.3 Asia Neuroendocrine Tumor Treatment Market Size by Application
9.3.1 Asia Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
9.3.2 Asia Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
9.3.3 Asia Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
9.4 Asia Neuroendocrine Tumor Treatment Market Size by Region
9.4.1 Asia Neuroendocrine Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Neuroendocrine Tumor Treatment Market Size by Region (2019-2024)
9.4.3 Asia Neuroendocrine Tumor Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Exelixis, Inc.
11.1.1 Exelixis, Inc. Company Details
11.1.2 Exelixis, Inc. Business Overview
11.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Introduction
11.1.4 Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.1.5 Exelixis, Inc. Recent Developments
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Details
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Introduction
11.2.4 Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.2.5 Advanced Accelerator Applications Recent Developments
11.3 Dauntless Pharmaceuticals, Inc.
11.3.1 Dauntless Pharmaceuticals, Inc. Company Details
11.3.2 Dauntless Pharmaceuticals, Inc. Business Overview
11.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.3.4 Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.3.5 Dauntless Pharmaceuticals, Inc. Recent Developments
11.4 Hutchinson Medipharma Limited
11.4.1 Hutchinson Medipharma Limited Company Details
11.4.2 Hutchinson Medipharma Limited Business Overview
11.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Introduction
11.4.4 Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.4.5 Hutchinson Medipharma Limited Recent Developments
11.5 Ispen
11.5.1 Ispen Company Details
11.5.2 Ispen Business Overview
11.5.3 Ispen Neuroendocrine Tumor Treatment Introduction
11.5.4 Ispen Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.5.5 Ispen Recent Developments
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Neuroendocrine Tumor Treatment Introduction
11.6.4 Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.6.5 Novartis AG Recent Developments
11.7 Progenics Pharmaceuticals, Inc.
11.7.1 Progenics Pharmaceuticals, Inc. Company Details
11.7.2 Progenics Pharmaceuticals, Inc. Business Overview
11.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.7.4 Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.7.5 Progenics Pharmaceuticals, Inc. Recent Developments
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Introduction
11.8.4 Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.8.5 Tarveda Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る


 

Summary

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

Market Analysis and Insights: Global Neuroendocrine Tumor Treatment Market
The global Neuroendocrine Tumor Treatment market is projected to grow from US$ 1632.2 million in 2024 to US$ 2302.3 million by 2030, at a Compound Annual Growth Rate (CAGR) of 5.9% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:
This report presents an overview of global market for Neuroendocrine Tumor Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Neuroendocrine Tumor Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neuroendocrine Tumor Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Tumor Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Neuroendocrine Tumor Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Neuroendocrine Tumor Treatment revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation
By Company
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics
Segment by Type
Everolimus
Sunitinib
Lu-Dotatate
Lanreotide
Octreotide
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neuroendocrine Tumor Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Tumor Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions



ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Everolimus
1.2.3 Sunitinib
1.2.4 Lu-Dotatate
1.2.5 Lanreotide
1.2.6 Octreotide
1.3 Market by Application
1.3.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Tumor Treatment Market Perspective (2019-2030)
2.2 Global Neuroendocrine Tumor Treatment Growth Trends by Region
2.2.1 Neuroendocrine Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neuroendocrine Tumor Treatment Historic Market Size by Region (2019-2024)
2.2.3 Neuroendocrine Tumor Treatment Forecasted Market Size by Region (2025-2030)
2.3 Neuroendocrine Tumor Treatment Market Dynamics
2.3.1 Neuroendocrine Tumor Treatment Industry Trends
2.3.2 Neuroendocrine Tumor Treatment Market Drivers
2.3.3 Neuroendocrine Tumor Treatment Market Challenges
2.3.4 Neuroendocrine Tumor Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Neuroendocrine Tumor Treatment by Players
3.1.1 Global Neuroendocrine Tumor Treatment Revenue by Players (2019-2024)
3.1.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neuroendocrine Tumor Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neuroendocrine Tumor Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Neuroendocrine Tumor Treatment Market Concentration Ratio
3.4.1 Global Neuroendocrine Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Treatment Revenue in 2023
3.5 Global Key Players of Neuroendocrine Tumor Treatment Head office and Area Served
3.6 Global Key Players of Neuroendocrine Tumor Treatment, Product and Application
3.7 Global Key Players of Neuroendocrine Tumor Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Tumor Treatment Breakdown Data by Type
4.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Type (2019-2024)
4.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Type (2025-2030)
5 Neuroendocrine Tumor Treatment Breakdown Data by Application
5.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Application (2019-2024)
5.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neuroendocrine Tumor Treatment Market Size (2019-2030)
6.2 North America Neuroendocrine Tumor Treatment Market Size by Type
6.2.1 North America Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
6.2.2 North America Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
6.2.3 North America Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
6.3 North America Neuroendocrine Tumor Treatment Market Size by Application
6.3.1 North America Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
6.3.2 North America Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
6.3.3 North America Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
6.4 North America Neuroendocrine Tumor Treatment Market Size by Country
6.4.1 North America Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
6.4.3 North America Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Neuroendocrine Tumor Treatment Market Size (2019-2030)
7.2 Europe Neuroendocrine Tumor Treatment Market Size by Type
7.2.1 Europe Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
7.2.2 Europe Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
7.2.3 Europe Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
7.3 Europe Neuroendocrine Tumor Treatment Market Size by Application
7.3.1 Europe Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
7.3.2 Europe Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
7.3.3 Europe Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
7.4 Europe Neuroendocrine Tumor Treatment Market Size by Country
7.4.1 Europe Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
7.4.3 Europe Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Neuroendocrine Tumor Treatment Market Size (2019-2030)
8.2 China Neuroendocrine Tumor Treatment Market Size by Type
8.2.1 China Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
8.2.2 China Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
8.2.3 China Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
8.3 China Neuroendocrine Tumor Treatment Market Size by Application
8.3.1 China Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
8.3.2 China Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
8.3.3 China Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Neuroendocrine Tumor Treatment Market Size (2019-2030)
9.2 Asia Neuroendocrine Tumor Treatment Market Size by Type
9.2.1 Asia Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
9.2.2 Asia Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
9.2.3 Asia Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
9.3 Asia Neuroendocrine Tumor Treatment Market Size by Application
9.3.1 Asia Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
9.3.2 Asia Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
9.3.3 Asia Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
9.4 Asia Neuroendocrine Tumor Treatment Market Size by Region
9.4.1 Asia Neuroendocrine Tumor Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Neuroendocrine Tumor Treatment Market Size by Region (2019-2024)
9.4.3 Asia Neuroendocrine Tumor Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Neuroendocrine Tumor Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Exelixis, Inc.
11.1.1 Exelixis, Inc. Company Details
11.1.2 Exelixis, Inc. Business Overview
11.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Introduction
11.1.4 Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.1.5 Exelixis, Inc. Recent Developments
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Details
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Introduction
11.2.4 Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.2.5 Advanced Accelerator Applications Recent Developments
11.3 Dauntless Pharmaceuticals, Inc.
11.3.1 Dauntless Pharmaceuticals, Inc. Company Details
11.3.2 Dauntless Pharmaceuticals, Inc. Business Overview
11.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.3.4 Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.3.5 Dauntless Pharmaceuticals, Inc. Recent Developments
11.4 Hutchinson Medipharma Limited
11.4.1 Hutchinson Medipharma Limited Company Details
11.4.2 Hutchinson Medipharma Limited Business Overview
11.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Introduction
11.4.4 Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.4.5 Hutchinson Medipharma Limited Recent Developments
11.5 Ispen
11.5.1 Ispen Company Details
11.5.2 Ispen Business Overview
11.5.3 Ispen Neuroendocrine Tumor Treatment Introduction
11.5.4 Ispen Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.5.5 Ispen Recent Developments
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Neuroendocrine Tumor Treatment Introduction
11.6.4 Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.6.5 Novartis AG Recent Developments
11.7 Progenics Pharmaceuticals, Inc.
11.7.1 Progenics Pharmaceuticals, Inc. Company Details
11.7.2 Progenics Pharmaceuticals, Inc. Business Overview
11.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.7.4 Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.7.5 Progenics Pharmaceuticals, Inc. Recent Developments
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Introduction
11.8.4 Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2019-2024)
11.8.5 Tarveda Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る